The United Kingdom Facioscapulohumeral Muscular Dystrophy Patient Registry

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorNewcastle University

About this trial

Facioscapulohumeral Dystrophy (FSHD) is the third most common form of neuromuscular dystrophy worldwide with an estimated prevalence of one in 20,000. FSHD is an autosomal dominant genetic disease and is estimated to affect up to 3,000 people in the UK.

The patient registry facilitates a questionnaire based research study to better characterise and understand the disease in the UK, and helps to identify potential participants eligible for clinical trials.

Eligibility criteria

Qualifiers

None

Disqualifiers

Any confirmed NMD other than FSHD

Living outside of the UK

Trial design

Treatments tested in this trial

  • Patient Registry

Treatment groups

1,018 Participants
are divided into 1 treatment group

Sponsors and collaborators